Health Canada recently gave updates to 27 monographs and provided notice of extended licence processing timelines. Read more to ensure compliance with the latest NNHPD updates.
In November 2017, the NNHPD made revisions to risk information for the Green Tea Extract monograph, based on a Health Canada safety summary review for products containing Green Tea extract that identified the need for more cautionary statements for this ingredient.
The changes applicable for this ingredient are indicated in bold as follows, in order to enhance the previous risk information:
Plus the addition of the following risk information:
Submitting a Green Tea Monograph Attestation Form and labelling of the revised green tea extract risk statements is required for all marketed products with this medicinal ingredient—and has a deadline of November 14, 2018. The attestation is to be signed by the Senior Official of the licence holder/company to confirm awareness of making the above-noted updates to the product licence and label. The attestation form requests the quantity per dosage unit of green tea extract and of the Epigallocatechin gallate (EGCG) provided from the green tea extract. If the attestation form is not submitted, or product labels are not updated by this date, further compliance and enforcement action may be initiated by the NNHPD (i.e. section 16 notice).
The NNHPD has revised 26 of their monographs by making various changes for each, including changes to the “statements to the effect of” for claims, warnings, and other product statements. Please see the following list of monograph updates for any new submissions you may be compiling or for any updates you are looking to make for your existing product licence/s:
In June 2018, the NNHPD communicated a Notice to Industry regarding improving the efficiency and predictability of the management process for Natural Health Product Licence Applications. This decision to revise the standards was based on various considerations, such as higher application volumes, deficient applications, increased paper submission, etc… In the Notice, the NNHPD indicated updates to their review timelines as follows, notably affecting the Class 1 and Class 2 submissions timelines:
For more assistance in determining if your product requires label updates or if you are interested in filing an amendment to your existing licence based on the updated NNHPD monographs, contact dicentra for assistance and for more information by filling the form below.
dicentra provides sought-after guidance on product and marketing compliance, quality assurance and safety standards, research and development, new ingredient assessments and overall regulatory strategies for food and health-related products sold in North American marketplaces. We can also assist you with your classification determinations for delivery systems or combination drug-device products. We can be reached at 1-866-647-3279 or email@example.com.